0001209191-22-036485.txt : 20220613
0001209191-22-036485.hdr.sgml : 20220613
20220613195213
ACCESSION NUMBER: 0001209191-22-036485
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220610
FILED AS OF DATE: 20220613
DATE AS OF CHANGE: 20220613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39756
FILM NUMBER: 221013128
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Silverback Therapeutics, Inc.
CENTRAL INDEX KEY: 0001671858
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811489190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 FAIRVIEW AVENUE NORTH, SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-456-2900
MAIL ADDRESS:
STREET 1: 500 FAIRVIEW AVENUE NORTH, SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-10
0
0001671858
Silverback Therapeutics, Inc.
SBTX
0001357522
Thompson Peter A.
C/O SILVERBACK THERAPEUTICS, INC.
500 FAIRVIEW AVENUE N, SUITE 600
SEATTLE
WA
98109
1
0
1
0
Stock Option (right to buy)
4.18
2022-06-10
4
A
0
18000
0.00
A
2032-06-09
Common Stock
18000
18000
D
The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.
/s/ Jeffrey C. Pepe, Attorney-in-Fact
2022-06-13